Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.52 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8422540 | 0.93 | KCNA3 (0.61) | FFAR1TDP1DRD2DRD4DRD3 | |
| SCHEMBL14463902 | 0.91 | FFAR1 (0.62) | FFAR1TDP1S1PR1S1PR3S1PR5 | |
| SCHEMBL4521863 | 0.87 | KCNA3 (0.59) | FFAR1S1PR1S1PR3S1PR5DRD2 | |
| SCHEMBL9442260 | 0.86 | KCNA3 (0.53) | FFAR1TDP1S1PR1DRD2DRD4 | |
| SCHEMBL10741496 | 0.86 | FFAR1 (0.55) | FFAR1S1PR1S1PR3S1PR5DRD2 | |
| SCHEMBL10738553 | 0.86 | FFAR1 (0.55) | FFAR1S1PR1S1PR3S1PR5DRD2 | |
| SCHEMBL10733620 | 0.85 | FFAR1 (0.56) | FFAR1TDP1DRD2DRD4DRD3 | |
| SCHEMBL4981505 | 0.85 | KCNA3 (0.73) | FFAR1S1PR1S1PR3S1PR5DRD2 | |
| SCHEMBL7474215 | 0.84 | FFAR1 (0.61) | FFAR1S1PR1S1PR3S1PR5DRD2 | |
| SCHEMBL7619641 | 0.84 | FFAR1 (0.66) | FFAR1TDP1S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105309-A1 | Medicinal Compounds | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| EP-1675823-B1 | PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| EP-1497261-B1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-7271197-B2 | Phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-18 | — | — | US | disclosed |
| EP-1675823-A1 | MEDICINAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| US-20050256201-A1 | Phenethanolamine derivatives | GLAXO GROUP LIMITED | 2005-11-17 | — | — | US | disclosed |
| WO-2005040103-A1 | MEDICINAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-05-06 | — | — | WO | disclosed |
| EP-1497261-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003091204-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256201-A1 | Phenethanolamine derivatives | PNMT, PHOSPHO1, NAPEPLD | FFAR1 1108/4885TDP1 3436/4885S1PR1 402/4885 |
| US-20090105309-A1 | Medicinal Compounds | ADRB2, ADRB1, ADRB3 | FFAR1 264/4885TDP1 4766/4885S1PR1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.